Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia
暂无分享,去创建一个
Ian Law | Marina Boccardi | Federica Agosta | Flavio Nobili | Zuzana Walker | Giovanni Battista Frisoni | Alexander Drzezga | Javier Arbizu | Stefania Orini | Peter J Nestor | G. Frisoni | A. Drzezga | F. Agosta | F. Bouwman | P. Nestor | D. Altomare | F. Nobili | J. Arbizu | I. Law | M. Boccardi | Z. Walker | C. Festari | S. Orini | Femke Bouwman | Cristina Festari | Daniele Altomare | Jasmine Rivolta | Jasmine Rivolta
[1] R. Laforce,et al. The Value of PET in Mild Cognitive Impairment, Typical and Atypical/Unclear Dementias: A Retrospective Memory Clinic Study , 2010, American journal of Alzheimer's disease and other dementias.
[2] S. Goldman,et al. Combined magnetic resonance imaging– and positron emission tomography–guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients , 2000 .
[3] Alan J. Thomas,et al. Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.
[4] Cindee M. Madison,et al. Early 11C-PIB Frames and 18F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLD Patients , 2011, The Journal of Nuclear Medicine.
[5] H. Arai,et al. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies , 2012, Journal of the Neurological Sciences.
[6] Koen Van Laere,et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[7] R. Faber,et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.
[8] Karl Herholz,et al. 18F-FDG PET and Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias , 2014, The Journal of Nuclear Medicine.
[9] D. Loewenstein,et al. Sensitivity and specificity of positron emission tomography and magnetic resonance imaging studies in Alzheimer's disease and multi-infarct dementia. , 1989, European neurology.
[10] Nick C Fox,et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.
[11] Clifford R. Jack,et al. FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer’s Type , 2013, PloS one.
[12] Max Wintermark,et al. Recommendations for the Management of Cerebral and Cerebellar Infarction With Swelling: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2014, Stroke.
[13] Frontal Network Syndrome Testing , 2013, American journal of Alzheimer's disease and other dementias.
[14] J. Kornak,et al. Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .
[15] C. Weiller,et al. Syndrome‐Specific Patterns of Regional Cerebral Glucose Metabolism in Posterior Cortical Atrophy in Comparison to Dementia with Lewy Bodies and Alzheimer's Disease—A [F‐18]‐Fdg Pet Study , 2013, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[16] M. Fernández-Matarrubia,et al. Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes , 2015, Journal of Neurology.
[17] M. Freedman,et al. Frontotemporal lobar degeneration , 1998, Neurology.
[18] K. Ishii,et al. Cerebral glucose metabolism in patients with frontotemporal dementia. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] G. Hajak,et al. A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration , 2011, European Archives of Psychiatry and Clinical Neuroscience.
[20] S. Cho,et al. Subcortical Vascular versus Amnestic Mild Cognitive Impairment: Comparison of Cerebral Glucose Metabolism , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[21] K. Ishii,et al. Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer’s disease using FDG-PET and 3D-SSP , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[22] A. Drzezga,et al. Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits , 2015, The Journal of Nuclear Medicine.
[23] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[24] W. M. van der Flier,et al. Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort , 2015, Dementia and Geriatric Cognitive Disorders.
[25] J. Hatazawa,et al. Can PET Data Differentiate Alzheimer's Disease from Vascular Dementia? , 2000, Annals of the New York Academy of Sciences.
[26] Karl Herholz,et al. 18FDG PET in Vascular Dementia: Differentiation from Alzheimer's Disease Using Voxel-Based Multivariate Analysis , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[27] Luigi Gianolli,et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting , 2014, NeuroImage: Clinical.
[28] S. Black,et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.
[29] K. Ishii,et al. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). , 1999, Neuroreport.
[30] M. Brainin,et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2012 , 2004, European journal of neurology.
[31] Karl J. Friston,et al. A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia , 2014, Neuroinformatics.
[32] B. Miller,et al. Classification of primary progressive aphasia and its variants , 2011, Neurology.
[33] A. Drzezga,et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[34] C. Rowe,et al. The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies , 2009, Journal of Nuclear Medicine.
[35] Nick C Fox,et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia , 2012, European journal of neurology.
[36] A. Takeda,et al. [18F]FDG-PET study in dementia with lewy bodies and alzheimer's disease , 2001, Progress in Neuro-psychopharmacology and Biological Psychiatry.
[37] Satoshi Minoshima,et al. Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation , 2001, Annals of neurology.
[38] M. Hüll,et al. Posterior cortical atrophy: variant of Alzheimer’s disease? , 2005, Journal of Neurology.
[39] Nick C Fox,et al. The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .
[40] E. Huang,et al. Nonfluent/Agrammatic PPA with In-Vivo Cortical Amyloidosis and Pick’s Disease Pathology , 2013, Behavioural neurology.
[41] K. Leenders,et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases , 2010, Movement disorders : official journal of the Movement Disorder Society.
[42] F Nobili,et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus , 2018, European journal of neurology.
[43] J. Booij,et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[44] H. Zaidi,et al. Regions of Interest–Based Discriminant Analysis of DaTSCAN SPECT and FDG-PET for the Classification of Dementia , 2013, Clinical nuclear medicine.
[45] G. Frisoni,et al. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[46] V. Lowe,et al. Clinical, FDG and amyloid PET imaging in posterior cortical atrophy , 2015, Journal of Neurology.
[47] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[48] A. Drzezga,et al. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[49] A. Drzezga,et al. EANM-EAN recommendations for the use of brain 18 F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus , 2018 .
[50] G. Frisoni,et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[51] Stefano F. Cappa,et al. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia , 2014, NeuroImage: Clinical.
[52] W. M. van der Flier,et al. The Added Value of 18-Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of the Behavioral Variant of Frontotemporal Dementia , 2014, American journal of Alzheimer's disease and other dementias.
[53] Kenya Murase,et al. Comparison of Regional Brain Volume and Glucose Metabolism Between Patients with Mild Dementia with Lewy Bodies and Those with Mild Alzheimer's Disease , 2007, Journal of Nuclear Medicine.
[54] Nobuyuki Okamura,et al. Glucose Hypometabolism and Neuropathological Correlates in Brains of Dementia with Lewy Bodies , 2000, Experimental Neurology.
[55] J. O'Brien,et al. An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy , 2016, British Journal of Psychiatry.
[56] S. Gilman,et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] Hiroaki Kazui,et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography , 1997, Neuroscience Letters.
[58] S. Kushwaha,et al. Differential Diagnosis of Neurodegenerative Dementias Using Metabolic Phenotypes on F-18 FDG PET/CT , 2014, The neuroradiology journal.
[59] I. Lemahieu,et al. Differential Regional Cerebral Uptake of 18F-Fluoro-2-Deoxy-D-Glucose in Alzheimer’s Disease and Frontotemporal Dementia at Initial Diagnosis , 2001, European Neurology.
[60] O Sabri,et al. Correlation of neuropsychological, morphological and functional (regional cerebral blood flow and glucose utilization) findings in cerebral microangiopathy. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[61] J. Cummings,et al. Dementia with Leukoaraiosis: Clinical Differentiation by Temporoparietal Hypometabolism on 18FDG-PET Imaging , 1999, Dementia and Geriatric Cognitive Disorders.
[62] Gereon R. Fink,et al. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern , 1994, European Journal of Nuclear Medicine.
[63] Karen M Rodrigue,et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.
[64] K. Ishii,et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease , 1998, Neurology.
[65] G. Frisoni,et al. Assessing accuracy diagnostic FDG-PET studies to define clinical use for dementia diagnosis , 2018 .
[66] E. Reiman,et al. Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.
[67] R. Albin,et al. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease , 1996, Neurology.
[68] D. Perani,et al. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[69] W. Jagust,et al. Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease. , 2008, Archives of neurology.
[70] K. Herholz,et al. Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. , 1994, Electroencephalography and clinical neurophysiology.
[71] Cindee M. Madison,et al. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology , 2014, NeuroImage: Clinical.
[72] P. Panegyres,et al. Fluorodeoxyglucose-Positron Emission Tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study , 2009, BMC neurology.
[73] T. Murakami,et al. Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition , 2014, Annals of Nuclear Medicine.
[74] A. Drzezga,et al. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[75] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[76] Ignace Lemahieu,et al. Positron emission tomography in vascular dementia , 1998, Journal of the Neurological Sciences.
[77] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[78] Y. Hirayasu,et al. Clinical profiles of dementia with Lewy bodies with and without Alzheimer's disease‐like hypometabolism , 2015, International journal of geriatric psychiatry.
[79] I. McKeith,et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[80] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[81] B. Boeve,et al. Frontotemporal Dementia Mimicking Dementia With Lewy Bodies , 2008, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.
[82] C. Jack,et al. Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[83] Murray Grossman,et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.
[84] M. Brainin,et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004 * , 2004, European journal of neurology.
[85] C. DeCarli,et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.
[86] Nonfluent/Agrammatic PPA with In-Vivo Cortical Amyloidosis and Pick’s Disease Pathology , 2013, Behavioural neurology.
[87] D. Perani,et al. The Semantic Variant of Primary Progressive Aphasia: Clinical and Neuroimaging Evidence in Single Subjects , 2015, PloS one.
[88] R. Laforce,et al. Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes. , 2015, Journal of Alzheimer's disease : JAD.
[89] S. Gilman,et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing , 2005, Experimental Neurology.
[90] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[91] Michael Weiner,et al. Effects of white matter lesions and lacunes on cortical function. , 2004, Archives of neurology.
[92] K. Ishii,et al. Occipital Glucose Metabolism in Dementia with Lewy Bodies with and without Parkinsonism: A Study Using Positron Emission Tomography , 2001, Dementia and Geriatric Cognitive Disorders.
[93] V. Dhawan,et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography , 2013, Neuroradiology.
[94] J. Cummings,et al. Cortical Abnormalities Associated With Subcortical Lesions in Vascular Dementia: Clinical and Positron Emission Tomographic Findings , 1995 .
[95] A. Mishra,et al. Spectrum of neurocognitive dysfunction in Indian population on FDG PET/CT imaging , 2011, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.